AUCATZYL® (obecabtagene autoleucel) approved by US FDA on November 8, ahead of target PDUFA date of November 16; US commercial launch initiatedBLA approval triggers $30m milestone payment to Autolus from Blackstone Marketing authorizations for obe-cel under review with both the MHRA EMAMatthias Will M.D. appointed as Chief Development Officer, effective September 30, 2024Conference call to be held today at 08:30 am EDT/13:30 pm BST: conference call participants should pre-register using the link at the bottom of this press release LONDON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), an early commercial-stage biopharmaceutical company developing next-generation

AUCATZYL is the first CAR T therapy approved by the FDA with no requirement for a REMS program (Risk Evaluation Mitigation Strategy)Approval based on FELIX clinical trial of obe-cel in adult patients with r/r B-ALLConference call to be held on November 11 at 08:30 am EST/13:30 pm BST: conference call participants should pre-register using the link at the bottom of this press release LONDON, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), an early-commercial stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces the U.S. Food and Drug Administration (FDA) has granted marketing approval for AUCATZYL® (obecabtagen

LONDON, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announces the online publication of four abstracts submitted to the American Society of Hematology (ASH) Annual Meeting, to be held from December 7-10, 2024, in San Diego. "The FELIX study's rich data set continues to provide important information in shaping our understanding of the use of obe-cel to treat adult r/r B-ALL patients," said Dr. Christian Itin, Chief Executive Officer of Autolus. "We are presenting additional data at ASH that suggests deep molecular remission that may predict better outcomes; s

LONDON, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its third quarter 2024 financial results and operational highlights before open of US markets on Tuesday, November 12, 2024. Management will host a conference call and webcast at 8:30 am EDT/1:30 pm BST to discuss the company's financial results and provide a general business update. Conference call participants should pre-register using this link to receive the dial-in numbers and a personal PIN, which are required to access the conference call. A simultaneous audio webcas

Findings suggest the potential for obe-cel treatment without the need for consolidative SCTObe-cel given as a sole treatment to patients with lower tumor burden at lymphodepletion was associated with better outcomes LONDON, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announces a poster presentation at the 2024 Lymphoma, Leukemia & Myeloma Congress being held October 16-19, 2024, in New York. These data suggest that adult patients with relapsed/refractory B-Cell Acute Lymphoblastic Leukemia (r/r B-ALL) achieve comparable outcomes irrespective of the timing of s

LONDON, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announced the appointment of Matthias Will, M.D., as Chief Development Officer. Dr. Will is joining Autolus' executive team and will lead the company's development organization effective September 30, 2024. "Matthias has a proven track record of success in pharmaceutical product development, achieving many key regulatory milestones and marketing approvals across several cancer indications," said Dr. Christian Itin, Chief Executive Officer of Autolus. "His in-depth development experience and leadership skil

Tumor Burden (TB)-guided dosing strategy, together with the unique fast off-rate binder of obe-cel, resulted in substantial response and low incidence of Grade ≥3 immunotoxicityTB-guided dosing of obe-cel in the FELIX Phase Ib/II study demonstrated high CAR T-cell expansionPeak expansion was reached after Dose 2 in both low and high TB groups, demonstrating the positive effect from both doses of obe-cel, irrespective of TB at lymphodepletion LONDON, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announces a poster presentation at the Society of Hematologic Onco

On track for potential US commercial launch of obe-cel; PDUFA date November 16, 2024Longer follow up and subset analyses from pivotal FELIX Phase 2 data presented at ASCO and EHA; majority of responders showed durable responses; 40% of patients in ongoing remission without subsequent stem cell transplant (SCT) or other intervention A Market Authorization Application (MAA) for obe-cel in relapsed/refractory r/r adult B-cell Acute Lymphoblastic Leukemia (B-ALL) was submitted to the Medicine and Healthcare products Regulatory Authority (MHRA) in the UK at the end of July 2024. The MAA review process continues with the European Medicines Agency (EMA)Conference call to be held today at 08:30 am E

LONDON, July 26, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its second quarter 2024 financial results and operational highlights before open of US markets on Thursday, August 8, 2024. Management will host a conference call and webcast at 8:30 am EDT/1:30 pm BST to discuss the company's financial results and provide a general business update. Conference call participants should pre-register using this link to receive the dial-in numbers and a personal PIN, which are required to access the conference call. A simultaneous audio webcast

LONDON, June 14, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces three abstracts to be presented at the European Hematology Association (EHA) Congress, June 13-16, 2024. "We are looking forward to presenting longer-term data from adult patients with r/r ALL treated with obe-cel in the FELIX study," said Dr. Christian Itin, Chief Executive Officer of Autolus. "The data indicate that with a median follow up of 21.5 months long-term event free and overall survival are stabilizing at around 40%, suggesting that obe-cel can potentially deliver durable responses

S-8 - Autolus Therapeutics plc (0001730463) (Filer)

10-Q - Autolus Therapeutics plc (0001730463) (Filer)

8-K - Autolus Therapeutics plc (0001730463) (Filer)

8-K - Autolus Therapeutics plc (0001730463) (Filer)

8-K - Autolus Therapeutics plc (0001730463) (Filer)

8-K - Autolus Therapeutics plc (0001730463) (Filer)

8-K - Autolus Therapeutics plc (0001730463) (Filer)

10-Q - Autolus Therapeutics plc (0001730463) (Filer)

8-K - Autolus Therapeutics plc (0001730463) (Filer)

8-K - Autolus Therapeutics plc (0001730463) (Filer)

LONDON, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announced the appointment of Matthias Will, M.D., as Chief Development Officer. Dr. Will is joining Autolus' executive team and will lead the company's development organization effective September 30, 2024. "Matthias has a proven track record of success in pharmaceutical product development, achieving many key regulatory milestones and marketing approvals across several cancer indications," said Dr. Christian Itin, Chief Executive Officer of Autolus. "His in-depth development experience and leadership skil

LONDON, April 01, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces the appointment of Mike Bonney as Chairman of the Board, and Ravi Rao M.D., as Non-Executive Director. John H. Johnson advised the Board of his decision to step down from his role as Chairman of the Board and Non-Executive Director. These changes are effective as of today, April 1, 2024. "On behalf of the Board and Management team, we would like to thank John for his leadership during a transformational period for the Company, which included conducting the pivotal Phase 2 FELIX study and th

LONDON, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the appointment of Robert W. Azelby to the Board of Directors. Mr. Azelby brings more than 30 years of biopharmaceutical leadership and commercial experience to Autolus's Board. "The Autolus Board and Management Team would like to welcome Bob Azelby to the Board of Directors. Bob brings with him a wealth of experience and a strong track record in building successful biotech companies and his extensive commercial experience will be invaluable as we get closer to commercializing our first product,

-  Appointment of Elisabeth ("Lis") Leiderman, M.D. -  Resignation of Kapil Dhingra, M.D. LONDON, Dec. 22, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the appointment of Elisabeth Leiderman, M.D. to the Board of Directors. Additionally, the Company announced that Kapil Dhingra M.D., who has served on Autolus' Board of Directors since May 2015, has advised the Board of his intent to step down from his role as a member of the Board and chair of the Nominating and Corporate Governance Committee of the Board, effective December 31, 2023. "The Autolus

- Veronica Hersberger appointed as Senior Vice President, Medical Affairs- Miranda Neville promoted to Senior Vice President, Project Management and will continue to lead the obe-cel program LONDON, July 19, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the appointment of Robert F. Dolski as Chief Financial Officer (CFO), effective August 7, 2023. Mr. Dolski joins Autolus from Checkmate Pharmaceuticals Inc., where he served as Chief Financial Officer at the clinical-stage immuno-oncology biotech, acquired by Regeneron Pharmaceuticals Inc. in 2022. He bring

LONDON, June 20, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that Dr. Robert Iannone, Executive Vice President, Global Head of Research & Development of Jazz Pharmaceuticals plc, has been appointed as a Non-Executive Director to Autolus' Board of Directors, effective as of June 15, 2023. Dr. Iannone will serve as a Class I Director, with an initial term expiring at Autolus' 2025 Annual General Meeting. Dr. Iannone brings to Autolus a wealth of experience in the life science industry, having worked across a broad range of therapeutic areas and phases of de

- Dr. Lucinda Crabtree to step down with effect from Q3 2023 – - Search for new CFO has been initiated - LONDON, March 14, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that Dr. Lucinda Crabtree has provided notice of her resignation as Chief Financial Officer of the Company to pursue a new opportunity. Dr Crabtree will remain with the Company until Q3, 2023 in order to ensure a smooth and orderly transition. Autolus has initiated a formal search process for the selection of a new Chief Financial Officer. "I would like to thank Lucinda for the many valuab

- Andrew J. Oakley to retire in March 2022 - Dr. Lucinda Crabtree to succeed him as chief financial officer LONDON, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announced that Andrew J. Oakley plans to retire from his position as chief financial officer with effect from 31 March 2022 and will concentrate on non-executive director roles. He currently serves on the Boards of Union Therapeutics A/S and Novaremed AG. Andrew will remain a senior advisor to Autolus until March 2023. Dr. Lucinda Crabtree, senior vice president of finance at Autolus, will be appointed c

LONDON, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that Dr. William D. Young, a Senior Advisor to Blackstone Life Sciences, has been appointed as a non-executive director to its board of directors, effective immediately. The appointment is pursuant to the recently announced investment from Blackstone Life Sciences. Dr. Young will serve as a Class III director, with an initial term expiring at Autolus' 2024 annual general meeting. Dr. Young brings to Autolus more than 50 years of experience in the life science industry, most notably prior service

LONDON, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that John H. Johnson has been appointed as non-executive chairman of its Board of Directors, effective September 15, 2021. Dr. Martin Murphy, who previously served as chairman, will continue to serve as a non-executive Board member. Mr. Johnson brings to Autolus more than 30 years of experience in the life science industry. He is currently chief executive officer and a director of Strongbridge Biopharma plc, a NASDAQ listed commercial stage biopharmaceutical company. He previously served as the

Goldman upgraded Autolus Therapeutics from Neutral to Buy and set a new price target of $7.60 from $7.00 previously

Redburn Atlantic upgraded Autolus Therapeutics from Neutral to Buy and set a new price target of $13.00

Deutsche Bank initiated coverage of Autolus Therapeutics with a rating of Buy and set a new price target of $10.00

Wells Fargo resumed coverage of Autolus Therapeutics with a rating of Overweight and set a new price target of $8.00

Bryan Garnier initiated coverage of Autolus Therapeutics with a rating of Buy and set a new price target of $5.00

Jefferies upgraded Autolus Therapeutics from Hold to Buy and set a new price target of $12.00 from $6.00 previously

Needham reiterated coverage of Autolus Therapeutics with a rating of Buy and set a new price target of $21.00 from $26.00 previously

Redburn Partners resumed coverage of Autolus Therapeutics with a rating of Neutral

Redburn downgraded Autolus Therapeutics from Buy to Neutral

JP Morgan downgraded Autolus Therapeutics from Overweight to Neutral and set a new price target of $9.00

Analysts' ratings for Autolus Therapeutics (NASDAQ:AUTL) over the last quarter vary from bullish to bearish, as provided by 5 analysts. In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 5 0 0 0 0 Last 30D 1 0 0 0 0 1M Ago 1 0 0 0 0 2M Ago 1 0 0 0 0 3M Ago 2 0 0 0 0 The 12-month price targets, analyzed by analysts, offer insights with an average target of $9.4, a high estimate of $11.00, and a low estimate of $9.00. This current average reflects an increase of 1.62% from the previous

Needham analyst Gil Blum reiterates Autolus Therapeutics (NASDAQ:AUTL) with a Buy and maintains $9 price target.

Needham analyst Gil Blum reiterates Autolus Therapeutics (NASDAQ:AUTL) with a Buy and maintains $9 price target.

The majority of patients that responded to obe-cel showed durable responses with the potential for a long-term plateau of survival outcomes40% patients are in ongoing remission without subsequent stem cell transplant (SCT) or other interventionOngoing CAR T persistence was associated with improved event-free survivalAutolus will host a conference call and webcast to discuss the presented data on Saturday June 1, 2024 at 9:30 am EDT/8:30 am CDT/2:30 pm BST (details below)LONDON, May 31, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces longer-term follow-up and add

U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite falling around 50 points on Friday. The Dow traded up 0.12% to 39,917.54 while the NASDAQ fell 0.33% to 16,642.74. The S&P 500 also fell, dropping, 0.10% to 5,291.68.      . Check This Out: Walmart To Rally Over 17%? Here Are 10 Top Analyst Forecasts For Friday Leading and Lagging SectorsEnergy shares rose by 1.4% on Friday. In trading on Friday, information technology shares fell by 0.8%. Top Headline U.S. leading index fell 0.6% month-over-month for April, versus market expectations for a 0.3% decline. Equities Trading UP                        Autolus Therapeutics plc (NASDAQ:AUTL) shar

Shares of Cracker Barrel Old Country Store, Inc. (NASDAQ:CBRL) fell sharply during Friday's session after the company reduced its dividend and said it expects third-quarter and fourth-quarter results below its prior expectations. Cracker Barrel Old Country Store shares dipped 14.4% to $49.01 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers Fangdd Network Group Ltd. (NASDAQ:DUO) shares jumped 258.6% to $1.4709. FangDD filed 2023 annual report on Form 20-F. Akanda Corp. (NASDAQ:AKAN) jumped 129.4% to $0.3053 after jumping around 27% on Thursday. Crown ElectroKinetics Corp (NASDAQ:CRKN) shares jumped 89.6% to $0.4580. The stock has seen interes

Needham analyst Gil Blum reiterates Autolus Therapeutics (NASDAQ:AUTL) with a Buy and maintains $9 price target.

U.S. stocks were mixed, with the Dow Jones gaining around 0.1% on Friday. Shares of Despegar.com, Corp. (NYSE:DESP) rose sharply during Friday's session after the company reported better-than-expected quarterly sales results. Despegar.com posted GAAP earnings of 7 cents per share, versus market estimates of 15 cents per share. The company's quarterly sales came in at $173.700 million beating expectations of $171.556 million, according to data from Benzinga Pro. Despegar.com shares jumped 19.7% to $15.01 on Friday. Here are some other big stocks recording gains in today's session. Doximity, Inc. (NYSE:DOCS) gained 19.7% to $28.41 reported stronger-than-expected financial resul